01
Cash & equivalents increased 32.8%
Cash & equivalents changed +32.8% from the comparable as-filed period.
$154.5M→$205.1MComparable → current
· Biological Products, (No Diagnostic Substances)
RESEARCH SNAPSHOTZura Bio Ltd's latest supported as-filed period reports net income of -$26.3M, 64.5% below the comparable as-filed period. Every value below links to its SEC accession and metric lineage.
The most important deterministic changes, ranked by magnitude, issuer history, persistence, and accounting profile.
Cash & equivalents changed +32.8% from the comparable as-filed period.
Net income changed -64.5% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Operating income changed -62.3% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Each point keeps the date investors could first observe it and its accession.
ZURA · as filed with the SEC · reported-date aware
Direct SEC links, filing dates, report periods, and amendment flags.
0001104659-26-097526SEC ↗8-KAug 11, 2026Period Aug 11, 20260001855644-26-000007SEC ↗10-QAug 11, 2026Period Jun 30, 20260001855644-26-000006SEC ↗8-KJul 1, 2026Period Jul 1, 20260001104659-26-079538SEC ↗4Jun 22, 2026Period Jun 17, 20260001671311-26-000005SEC ↗4Jun 22, 2026Period Jun 17, 20260001995535-26-000008SEC ↗4Jun 22, 2026Period Jun 17, 20260001867508-26-000002SEC ↗Transaction semantics distinguish purchases, sales, awards, exercises, withholding, and derivatives.
| Filed / transacted | Reporting owner | Semantics | Shares | Price | Notional | Source |
|---|---|---|---|---|---|---|
| Jun 17, 2026Filed Jun 22, 2026 | Jarrett JenniferDirector | Grant Or AwardDirect | 51,000 | $0 | $0 | Form 4 ↗ |
GrossPattern stores immutable raw artifacts, accession-scoped facts, parser and metric versions, dependency edges, quality state, and channel-specific publication rights. A restricted or unknown ancestor blocks the page and API automatically.
SEC source policy ↗Research & development changed +137.9% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Stock-based compensation changed +19.4% from the comparable as-filed period. The change ranks at the 0th percentile of 4 prior comparable changes.
Method note “Materiality” here is an analytical magnitude band, not a legal conclusion. Full filing-text semantic changes remain unpublished while excerpt rights and review thresholds are unresolved.
Latest supported period in this snapshot: 2026-06-30. Duration facts use direct quarterly or annual SEC contexts; GrossPattern does not manufacture missing Q4 values.
0002116832-26-000007